HFSA 2021 - Cardiac Contractility Modulation - A New Category of Device-Based Interventional HF Therapy

November 25, 2021

This session from HFSA 2021 will explain what Cardiac Contractility Modulation therapy is, how it works, and what you can expect in terms of outcomes when utilizing this treatment for NYHA Class III patients who remain symptomatic in spite of guideline-directed medical therapy. Dr. John Boehmer discusses the problem of heart failure that still exists and the unmet need we still face (2:54 - 19:47). Dr. Jean-Bernard Durand breaks down the MoA of CCM® therapy and how it works (19:48 - 30:54). Dr. Javed Butler will provide an overview of the clinical trials both historical and ongoing as well as the future planned studies (30:55 - 50:31). Dr. Nirav Raval talks about his approach and experience of how to identify appropriate candidates for CCM therapy who have few or no other options available to them (50:32 - 1:02:09).

Introduction 0:00-2:53

John Boehmer, MD 2:54-19:47

JB Durand, MD 19:48-30:54

Javed Butler, MD 30:55-50:31

Nirav Raval, MD 50:32 -1:02:09

Q & A 1:02:10 -1:08:08
Login to view comments. Click here to Login